|
Daehan New Pharm achieved an operating profit of 9.4 billion won in the first half of the year, representing a 44% increase compared to the same period last year
2018.08.14
|
|---|
|
In the first half of 2018, Daehan New Pharm recorded sales of 61.469 billion won, a decrease of approximately 5% compared to the same period last year. However, operating profit rose significantly by about 44% to 9.46 billion won from 6.563 billion won in the previous year. Due to increased other expenses, the company recorded a net loss of 3.881 billion won.
Gradual improvements in financial structure and cost efficiency have steadily strengthened the company's fundamentals. The newly launched non-reimbursed injection ‘Same injection’ and the upcoming anticancer adjunct ‘Thymosin injection’ are expected to contribute to sales growth in the second half, supported by active seminars and both online and offline promotions. |


Home